For example, most ovarian cancer patients receive PTX chemotherapy, but only 42% of patients respond to PTX [43], and the relationship between CENPN and PTX resistance in ovarian cancer is also worthy of further study. This evidence concerns the gene CENPN and ovarian cancer.